Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 9
Submit an article Journal homepage
609
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma

Alyce M. Kuoa Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-6780-6506View further author information
ORCID Icon,
Hani Hassounb Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Urvi Shahb Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Allison Gordona Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Travis J. Hollmannc Dermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Heather J. Landaud Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-3152-1189View further author information
ORCID Icon,
Cecilia Lezcanoc Dermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Sham Mailankodyb Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Carlyn C. Tanb Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Alexander M. Lesokhinb Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-9321-702XView further author information
ORCID Icon &
Alina Markovaa Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2427-3199View further author information
ORCID Icon show all
Pages 2233-2237 | Received 22 Dec 2021, Accepted 09 Apr 2022, Published online: 09 May 2022

References

  • REVLIMID (lenalidomide) [package insert]. Summit (NJ): Celgene Corporation; 2019.
  • Nardone B, Wu S, Garden BC, et al. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk. 2013;13(4):424–429.
  • Kojima A, Tanaka Y, Kimura Y, et al. Multiple myeloma patients with lenalidomide-associated skin rash have a favorable prognosis. Blood. 2016;128(22):4532–4532.
  • Phan V, Ito T, Inaba M, et al. Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses. Blood Adv. 2020;4(15):3572–3585.
  • DUPIXENT (dupilumab) [package insert]. New York (NY): Regeneron Pharmaceuticals; 2020.
  • Lee MJ, Wickner P, Fanning L, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167(1):127–131.
  • Tinsley SM, Kurtin SE, Ridgeway JA. Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk. 2015;15 Suppl:S64–S69.
  • Yau P, Jimenez-Zepeda VH, Bailey K, et al. Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center. Leuk Lymphoma. 2019;60(13):3199–3203.
  • Sugi T, Mita M, Yasu T, et al. Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: case series. J Clin Pharm Ther. 2021;46(6):1792–1795.
  • Barley K, He W, Agarwal S, et al. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leuk Lymphoma. 2016;57(11):2510–2515.
  • Raza S, Safyan RA, Lentzsch S. Immunomodulatory drugs (IMiDs) in multiple myeloma. Curr Cancer Drug Targets. 2017;17(9):846–857.
  • Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293–1300.
  • Hong S, Qian J, Yang J, et al. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res. 2008;68(20):8456–8464.
  • Worm M, Simpson EL, Thaci D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131–143.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.